Goldman Sachs analyst Chris Shibutani upgraded United Therapeutics (UTHR) to Neutral from Sell with a price target of $215, up from $213. The analyst believes current share levels appropriately reflect the balance of potential positives and risks for the business over the near to intermediate term. The firm sees United Therapeutics’ franchise position within the “highly attractive” pulmonary arterial hypertension market as unique, but notes the potential for competitive pressures to its key growth asset, Tyvaso, from the anticipated entry of Merck’s (MRK) sotatercept and Liquidia’s (LQDA) Yutrepia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UTHR:
- Charter downgraded, Cigna upgraded: Wall Street’s top analyst calls
- United Therapeutics initiated with an Outperform at Leerink
- Liquidia files response and counterclaims to United Therapeutics lawsuit
- Biotech Alert: Searches spiking for these stocks today
- Liquidia price target raised to $30 from $15 at Ladenburg
